BioXcell熱銷產(chǎn)品--BE0273 InVivoMab anti-mouse PD-1 (CD279)
?
產(chǎn)品描述:
BioXcell InVivoMab anti-mouse PD-1 29F.1A12單克隆抗體與小鼠PD-1(也稱為CD279)反應(yīng)。PD-1是一種50-55kDa的細胞表面受體,由Pdcd1基因編碼,屬于Ig超家族的CD28家族。PD-1在CD4和CD8胸腺細胞以及活化的T和B淋巴細胞和髓細胞上瞬時表達,在成功消除抗原后PD-1的表達下降。此外,在B細胞前階段,Pdcd1 mRNA在發(fā)育中的B淋巴細胞中表達。PD-1的結(jié)構(gòu)包括ITIM(基于免疫受體酪氨酸的抑制基序),這表明PD-1負調(diào)控TCR信號。PD-1通過結(jié)合B7家族的成員PD-L1和PD-L2發(fā)出信號。在配體結(jié)合后,PD-1信號傳導抑制T細胞活化,導致增殖減少,細胞因子產(chǎn)生和T細胞死亡。此外,PD-1敲除動物表現(xiàn)出擴張型心肌病、脾腫大和外周耐受喪失,在小鼠的外周耐受性和預(yù)防自身免疫性疾病中發(fā)揮關(guān)鍵作用。誘導的PD-L1表達常見于許多腫瘤,包括鱗狀細胞癌、結(jié)腸癌和乳腺癌。PD-L1過度表達會導致腫瘤細胞對CD8T細胞介導的裂解的抗性增加。在黑素瘤的小鼠模型中,可以通過用阻斷PD-L1與其受體PD-1之間相互作用的抗體治療來暫時抑制腫瘤生長。由于這些原因,目前正在探索抗PD-1介導的免疫療法作為癌癥治療。與RMP1-14和J43抗體一樣,29F.1A12抗體在體內(nèi)阻斷PD-1與其配體的結(jié)合。
?
產(chǎn)品詳情:
產(chǎn)品名稱 | InVivoMAb anti-mouse PD-1 (CD279) |
產(chǎn)品貨號 | BE0273 |
產(chǎn)品規(guī)格 | 1/5/25/50/100mg |
反應(yīng)種屬 | Mouse |
克隆號 | 29F.1A12 |
同種型 | Rat IgG2a |
免疫原 | Recombinant PD-1-Ig fusion protein |
實驗應(yīng)用 | in vivo blocking of PD-1/PD-L signaling in vitro PD-1 neutralization Immunohistochemistry (frozen) Immunofluorescence Western blot Flow cytometry |
產(chǎn)品形式 | PBS, pH 7.0,Contains no stabilizers or preservatives |
純度 | >95%, Determined by SDS-PAGE |
無菌處理 | 0.2 μm filtration |
純化方式 | Protein G |
RRID | AB_2687796 |
分子量 | 150 kDa |
保存條件 | 抗體原液保存在4°C,不能冷凍保存。 |
推薦同型對照 | InVivoMAb rat IgG2a isotype control, anti-trinitrophenol(貨號BE0089) |
推薦抗體稀釋液 | InVivoPure pH 7.0 Dilution Buffer(貨號IP0070) |
該產(chǎn)品自上市已被多篇SCI文獻引用,品質(zhì)有保證,以下是部分已發(fā)表的文獻引用:
應(yīng)用 | 文章 |
體內(nèi)PD-1/PD-L信號阻斷 (in vivo blocking of PD-1/PD-L signaling) | 1.?Wang, W., et al. (2018). 'RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer' Cancer Cell 34(5): 757-774 e757. 2.?Gordon, S. R., et al. (2017). 'PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity' Nature 545(7655): 495-499. ? 3.?Koyama, S., et al. (2016). 'STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment' Cancer Res 76(5): 999-1008. |
體內(nèi)PD-1/PD-L信號阻斷,流式細胞術(shù) (in vivo blocking of PD-1/PD-L signaling, Flow Cytometry) | 1.Koyama, S., et al. (2016). 'Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints' Nat Commun 7: 10501. |
體外PD-1中和 (in vitro PD-1 neutralization) | 1.Park, S. J., et al. (2014). 'Negative role of inducible PD-1 on survival of activated dendritic cells' J Leukoc Biol 95(4): 621-629. |
體內(nèi)PD-1/PD-L信號阻斷,體外PD-1中和 (in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization) | 1.Duraiswamy, J., et al. (2013). 'Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors' Cancer Res 73(12): 3591-3603. |
流式細胞術(shù) (Flow Cytometry) | 1.Good-Jacobson, K. L., et al. (2012). 'CD80 expression on B cells regulates murine T follicular helper development, germinal center B cell survival, and plasma cell generation' J Immunol 188(9): 4217-4225. |
免疫熒光,免疫印跡 (Immunofluorescence, Western Blot) | 1.Chen, L., et al. (2009). 'Role of the immune modulator programmed cell death-1 during development and apoptosis of mouse retinal ganglion cells' Invest Ophthalmol Vis Sci 50(10): 4941-4948. |
免疫組織化學(冷凍) (Immunohistochemistry (frozen)) | 1.?Menke, J., et al. (2007). 'Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles' J Immunol 179(11): 7466-7477. 2.?Liang, S. C., et al. (2003). 'Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses' Eur J Immunol 33(10): 2706-2716. |
?
?
?
?
更多產(chǎn)品詳情請咨詢 BioXcell 中國授權(quán)代理——欣博盛生物
全國服務(wù)熱線: 4006-800-892 ? ? ??郵箱: market@neobioscience.com?
深圳: 0755-26755892 ? ? ? ??北京: 010-88594029 ???????????
廣州:020-87615159????????? ?上海: 021-34613729
代理品牌網(wǎng)站: m.yuebanme.com?
自主品牌網(wǎng)站: www.neobioscience.net